Despite a high chemosensitivity in ovarian cancer the 5-year-survival in advanced disease is below 20%. Resistance develops very early during chemotherapy. The actual EBMT-registry data are showing a 5-year survival of about 30% for patients with advanced ovarian cancer, who received one high dose consolidation chemotherapy after conventional treatment. One course of high dose chemotherapy after several cycles of conventional therapy might not be the best schedule for delivering high dose chemotherapy (HDCT). As resistance against cytotoxic drugs can be influenced and even resolved by dose escalation of the cytostatic agents it may be mandatory to treat with high doses from the onset of therapy and for a relative short time period.
Introduction: High-dose chemotherapy (HD-ctx) is effective in solid tumors of various origins. In view of the efficacy of single-shot HD-ctx regimen a logical step is to optimize the HD-ctx with the addition of non cross-toxic, synergistic drugs and determination of the MTD with PBSC. The ICE-regimen has yielded encouraging results in GCT, STS, SCLC, ovary and breast-ca. Paclitaxel (T) has not been widely used in HD-ctx, but phase-I trials have established a dose of 625 mg/m 2 as MTD with PBSC. Furthermore, T is effective at standard-doses in solid tumors and has a different mode of action and pattern of resistance compared to alkylating and platinum agents. We therefore included T in an established HD-regimen (ICE), starting dose-escalation below previously described MTDs.
Patients and methods:
We treated 16 pts with relapsed or refractory GCT (6) or STS (5), SCLC (2), breast-ca. (2) NHL (1) with high-dose chemotherapy dose-escalating paclitaxel (T) 175-225 mg/m 2 d1 and Ifo 2500-3000 mg/m 2 d1-3, Carbo AUC 7.5-15 d1-3, VP16 250-300 mg/m 2 d1-3. PBSC Ͼ2.5 × 10 6 CD34/kg were given d5, therapy was repeated day 21 for a maximum of 4 cycles. Inclusion-criteria: PS Ͻ2 WHO, age Ͻ60 y., no severe hepatic or renal dysfunction, PBSC Ͼ10 × 10 6 CD34/kg after induction-ctx (T/Ifo × 2), Ͼ MR after induction-ctx., no prior HD-ctx. Results: 16 pts received 51 courses of HD-ctx, 5 pts received 4, 9 received 3 cycles, 2 received only 2 cycles of HD-ctx. All pts were evaluable for response and toxicity. Reasons for not completing 4 cycles were: PD (1), pts request (3) , insufficient PBSC or unwillingness to undergo further apheresis (9).
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DL2 DL3 DL4 total N/cycles 9 9 30 3 51 N Cycles 0 0 5 3 n.a. tox Ͼ2 WHO 6/7 pts received 3 or 4 cycles of T-ICE (175/9000/900/900) at DL3. Escalation of T to 225 mg/m2 (DL4) led to grade 3/4 toxicity in 3/3 pts in the 1 st cycle and was DLT. Treatment was continued at DL 3 for the remaining cycles in these 3 pts. There was no treatment related mortality. Hemato-logical recovery was prompt. There was no significant delay of hematological recovery between the first and the following HD-cycles. Pioneered by investigators from Indiana University in the United States high-dose chemotherapy (HDCT) has been investigated as salvage treatment for germ cell tumours since 1985. Whereas this treatment was initially reserved for patients (pts) with multiple relapses who were considered incurable with conventional-dose treatment, the observed efficacy of HDCT even in intensively pretreated patients and the increasing knowledge in handling the sideeffects of this highly toxic treatment has shifted HDCT more upfront in treatment strategies of pts with germ cell tumours.
In the salvage setting three groups of patients can be identified who might profit from HDCT:
(1) Pts with inadequate response to first-line treatment.
(2) Pts who relapse after first-line treatment. (3) Pts with an inadequate response or relapse after conventional-dose salvage treatment.
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Since the first reports of HDCT in germ cell tumours, this treatment has been refined in sequential trials in the United States and Europe.
Optimising schedule and administration
In the initial trials HDCT has been administered in pts with multiple relapses. Consequently, little efforts was made to further explore conventional-dose treatment immediately prior to HDCT. With more experience and the inclusion of less intensively pretreated pts, however, conventional-dose salvage was added before HDCT in an attempt to achieve tumour control immediately prior to the administration of HDCT. Similarly, it was realised that the doses of carboplatin and in particular of etoposide that were used in the initial trials did not make use of the full dose-escalation that became feasible with stem cell reinfusion. The inclusion of less intensively treated pts, more experience with HDCT and better supportive care have all contributed to a decrease of the high treatment-related mortality of more than 20% that was reported from the early trials. The rates of toxic deaths should not exceed 3% at present. In the initial trials HDCT represented a combination of carboplatin and etoposide that was given during two sequential HDCT cycles. Other investigators have added either ifosfamide or cyclophosphamide as a third drug with the hope to increase the efficacy of HDCT even further. Whereas there is little doubt that the addition of a third drug will increase the toxicity of HDCT, a benefit of these "triple" HDCT combinations for germ cell tumours remains to be shown. Similarly, approaches to integrate new agents such as paclitaxel and thiotepa into HDCT combinations for the salvage treatment of germ cell tumours have been largely disappointing so far.
Source of stem cells
With the rapid progress in stem cell technology, progenitor cells that were harvested from the peripheral blood after conventional-dose salvage treatment have replaced bone marrow as the source of stem cells. This certainly resulted in a significantly faster trilineage reconstitution, less transfusion requirements and a shorter hospital stay. However, whether the issue of a potentially lower rate of tumour cell contamination with the use of peripheral blood progenitor cells will be relevant to germ cell tumours, remains to be shown. Prognostic factors for treatment response after HDCT Because of the substantial toxicities of HDCT, but also because of its efforts and expense, the need for prognostic factors became soon evident. Multivariate analysis of a large multicenter database identified the degree of refractoriness to conventional-dose cisplatin as the single most important adverse prognostic variable. However, other variables such as a mediastinal primary tumour, high levels of HCG and progressive disease at the time of HDCT also related to an adverse prognosis. Taken together the variables can clearly define a subgroup of pts with an extremely poor prognosis who are unlikely to profit even from HDCT.
Comparison to conventional-dose salvage
There is little argument that HDCT still offers a chance of cure for primary refractory (but not absolute refractory) pts, for pts who respond to conventional-dose salvage treatment, but who do not become disease-free as well as for pts with multiple relapses. Yet, whether HDCT is indeed superior to conventional-dose first salvage treatment in cisplatin-sensitive pts has never been conclusively shown. Preliminary data from an ongoing prospective randomised phase III trial in the salvage treatment of cisplatin-sensitive pts indicate that the treatment benefit from HDCT might be less than expected previously. This observation is supported by a recent retrospective analysis that matched pts after HDCT and conventional-dose first salvage treatment from two large independent databases. However, even a smaller than expected benefit may translate in an improved survival in relapsed and/or refractory pts whose chances for cure are still far from being satisfactory. Objective: In order to improve the currently poor prognosis of patients with SCLC, a pilot study was performed to assess the feasibilityof a tandem high dose chemotherapy with PBSCs in patients without distant metastases. Patients and methods: 18 patients received two cycles of PEI (cisplatin 90 mg/m 2 d1, etoposid 120 mg/m 2 d1-3, ifosfamid 1500 mg/m 2 d1-4). After the second PEI cycle peripheral blood stem cell collections (PBSC) were performed with minimaly 5 × 10 6 CD34+ cells/kg body weight. The PBSC were analysed by immune histochemistry, to detect single disseminated tumor cells. Subsequently, a tandem high dose chemotherapy with the CEC protocol (cyclofosfamid 2000 mg/m 2 d1-2, etoposid 700 mg/m 2 d1-3 and carboplatin 1200 mg/m 2 ) was given and each high dose CEC supported by at least 2.5 × 10 6 CD 34+ cells/kg body weight. After the second CEC cycle a thoracic radiotherapy with 45 Gy was applied. Results: 18 patients (12 males, 6 females, 12 LD, 6 ED I, median age 48 years) were recruited from 1/96 to 3/97. After two cycles of PEI, 9 patients achieved a CR and 9 a PR. The amount of PBSC varied between 2.8 and 40 × 10 6 CD34+ cells/kg body weight. No single disseminated tumor cells were detected. The first CEC cycle was given to 16 patients. 10 patients received the second CEC therapy. The recovery of hematopoiesis (leucocytes Ͼ1000, platelets Ͼ20.000) took 15 days after the first, and 17 days after the second high dose cycle. Main toxicities were mucositis WHO II-III in 10 patients and infections WHO II-III in 7 cases. No treatment related death was noticed. Median survival of all 18 patients was 17 months, the 2-year survival rate is currently 45%.
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Conclusion:
The tandem high dose chemotherapy in SCLC-patients is feasible. The toxicity is moderate and the collection of PBSC after two cycles of PEI was successfull in nearly all patients. After the high dose chemotherapy 10 S21 out of 16 patients achieved a complete remission and the actuarial 2-year survival rate of 45% is promising. However, a longer follow up will be necessary to draw definitive conclusions. A randomised comparison to standard chemotherapy has been initiated. Combination chemotherapy with anthracyclines and ifosfamide shows reproducible activity with response rates of up to 50% in adult patients with advanced soft tissue sarcomas. However, superiority over single-agent doxorubicin has not been established yet. Since no other active drugs are currently available for adult soft tissue sarcomas, a promising approach to improve treatment results could be a doseintensive or even high-dose therapy using anthracyclines and ifosfamide at the highest possible doses. Such a strategy is strongly supported by positive dose-response relationships for both drugs. Due to dose-limiting non-hematological toxicity, repetitive high-dose treatments rather than a single mega-dose therapy seem appropriate. In a previous phase II -study using ifosfamide 2.5 g/m 2 per day as a continuous infusion, days 1 to 5 and epirubicin 45 mg/m 2 per day as a continuous infusion, days 2 and 3 repeated every 3 weeks, a response rate of 52% with 22% CR was seen in 46 pts. Consecutively, a phase I -study using further encreased doses of both drugs with hematopoietic stem cell support was started. After one induction cycle of IFO/EPI in the above mentioned dosage, stem cells were harvested (1 to 3 leukaphereses with a median total of 14 × 10 6 CD34+ cells/kg) and up to 5 cycles of doseintensified IFO/EPI, followed by stem cell support (Ͼ2 × 10 6 CD34+ cells/kg) were given every 3 weeks. Cumulative doses of IFO and EPI were escalated in a stepwise manner in groups of 3 to 5 pts. depending on toxicity reaching 17.5 g/m 2 and 150 mg/m 2 per cycle, respectively. So far, 22 pts. (m:f = 14:8, age: 17 to 65 ys.) have been entered and a total of 69 dose-intensified cycles have been applied. Duration of leuko-penia and thombocytopenia was up to 6 and 7 days, respectively. Severe non-hemotological toxicity so far consisted of reversible grade 4 nephrotoxicity (1 pt., dose step 2) and reversible grade 4 hepatotoxicity (1 pt., dose step 3). Conclusions: Application of up to 5 cycles of dose-intensified chemotherapy with stem-cell support every 3 weeks is feasible without cumulative hematotoxicity or dose-limiting non-hematological toxicity. The outline of a planned phase III -study as well as an overview of ongoing trials and the current literature will be presented.
